Journal article · 2023 · Open access

The Assessment of Patient-Reported Outcomes for the Authorisation of Medicines in Europe: A Review of European Public Assessment Reports from 2017 to 2022

Michela Meregaglia, Francesco Benito Malandrini, Stefania Angelini, Oriana Ciani

Applied Health Economics and Health Policy, 21(6), 925–935 · Published 2 September 2023 · DOI 10.1007/s40258-023-00827-3

Open PDFView at the publisherCite this paper

In brief

“The Assessment of Patient-Reported Outcomes for the Authorisation of Medicines in Europe: A Review of European Public Assessment Reports from 2017 to 2022” is a 2023 journal article by Michela Meregaglia and 3 co-authors, published in Applied Health Economics and Health Policy. OpenAlex counts 35 citations as of 22 November 2026. It is open access under a CC BY-NC licence: the full text is free to read at Applied Health Economics and Health Policy.

Citations
35
Most cited in
2025 (15)
Field-weighted impact
5.14
References
28
Authors
4

Abstract

OBJECTIVES: Health regulators have progressively increased their attention and focus on patient-reported outcomes (PROs), driven by the diffusion of a patient-centred approach to the drug development process. This study investigates the consideration of PROs and their measures (PROMs) in the authorisation of medicines in Europe. METHODS: All medicines for human use authorised or refused by the European Medicines Agency (EMA) in the period 2017-2022 were identified, and corresponding European Public Assessment Reports (EPARs) were downloaded for review. Medicine and PROs/PROM characteristics were systematically recorded. A multivariate logistic regression was performed to identify variables associated with the use of patient-reported evidence in EPARs. RESULTS: Overall, 497 EPARs of authorised medicines and 19 EPARs of refused medicines were analysed; of these, 240 (48.3%) and 10 (52.6%), respectively, reported any use of PROs/PROMs (p = 0.710). For authorised medicines, the likelihood of using PROs/PROMs was negatively affected by generic (OR = 0.01, p < 0.001) and biosimilar status (OR = 0.46, p = 0.013) and positively affected by orphan status (OR = 1.41, p = 0.177). The use of PROMs (50.6% in 2017 vs 47.9% in 2022) did not show a clear pattern over the 6-year period considered (p = 0.758) and was particularly uncommon in some therapeutic areas (e.g., 15.2% in infectious diseases). A total of 816 dyads of PROs/PROMs were identified. On average each EPAR considered 1.6 (range: 0-14) instruments. Patient-reported outcomes were typically secondary (53.3%) and exploratory endpoints (18.8%); in one-third of cases (32.5%), they assessed generic quality of life. Among the PROMs, 227 (27.8%) targeted general population; EQ-5D (11.0%), SF-36/SF-12 (5.9%) and EORTC QLQ-C30 (5.6%) were the instruments most frequently used. CONCLUSIONS: This study suggests PROs/PROMs are considered in less than half of total medicine assessments and even more rarely in some disease areas. The adoption of PROs is key in EMA strategy to 2025 and would be facilitated by consensus development on their measures and optimisation of data collection.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Meregaglia, M., Malandrini, F. B., Angelini, S., & Ciani, O. (2023). The Assessment of Patient-Reported Outcomes for the Authorisation of Medicines in Europe: A Review of European Public Assessment Reports from 2017 to 2022. Applied Health Economics and Health Policy, 21(6), 925–935. https://doi.org/10.1007/s40258-023-00827-3

MLA 9

Meregaglia, Michela, et al. “The Assessment of Patient-Reported Outcomes for the Authorisation of Medicines in Europe: A Review of European Public Assessment Reports from 2017 to 2022.” Applied Health Economics and Health Policy, vol. 21, no. 6, 2023, pp. 925–935. https://doi.org/10.1007/s40258-023-00827-3.

Chicago

Meregaglia, Michela, Francesco Benito Malandrini, Stefania Angelini, and Oriana Ciani. 2023. “The Assessment of Patient-Reported Outcomes for the Authorisation of Medicines in Europe: A Review of European Public Assessment Reports from 2017 to 2022.” Applied Health Economics and Health Policy 21 (6): 925–935. https://doi.org/10.1007/s40258-023-00827-3.

Harvard

Meregaglia, M. et al. (2023) ‘The Assessment of Patient-Reported Outcomes for the Authorisation of Medicines in Europe: A Review of European Public Assessment Reports from 2017 to 2022’, Applied Health Economics and Health Policy, 21(6), pp. 925–935. doi:10.1007/s40258-023-00827-3.

IEEE

M. Meregaglia, F. B. Malandrini, S. Angelini, and O. Ciani, “The Assessment of Patient-Reported Outcomes for the Authorisation of Medicines in Europe: A Review of European Public Assessment Reports from 2017 to 2022,” Applied Health Economics and Health Policy, vol. 21, no. 6, pp. 925–935, 2023, doi: 10.1007/s40258-023-00827-3.

BibTeX

@article{meregaglia2023assessment,
  title     = {{The Assessment of Patient-Reported Outcomes for the Authorisation of Medicines in Europe: A Review of European Public Assessment Reports from 2017 to 2022}},
  author    = {Meregaglia, Michela and Malandrini, Francesco Benito and Angelini, Stefania and Ciani, Oriana},
  journal   = {Applied Health Economics and Health Policy},
  year      = {2023},
  volume    = {21},
  number    = {6},
  pages     = {925--935},
  doi       = {10.1007/s40258-023-00827-3},
  url       = {https://doi.org/10.1007/s40258-023-00827-3}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202311
202477
20251515
20261212

Its field-weighted citation impact is 5.14: it has been cited 5.14 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life

  • patient-reported outcomes
  • patient-reported outcome measures
  • European Public Assessment Reports
  • European Medicines Agency
  • drug approval
  • regulatory decision-making
  • quality of life
  • health-related quality of life

Work with this paper

Most-cited papers in Economics, Econometrics and Finance

All highly cited Economics, Econometrics and Finance papers

Questions about this paper

How do I cite this paper in APA style?

Meregaglia, M., Malandrini, F. B., Angelini, S., & Ciani, O. (2023). The Assessment of Patient-Reported Outcomes for the Authorisation of Medicines in Europe: A Review of European Public Assessment Reports from 2017 to 2022. Applied Health Economics and Health Policy, 21(6), 925–935. https://doi.org/10.1007/s40258-023-00827-3

How many times has this paper been cited?

35 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Applied Health Economics and Health Policy: sign in and open the PDF from this page.

Who wrote this paper?

Michela Meregaglia, Francesco Benito Malandrini, Stefania Angelini, Oriana Ciani.

What is the DOI of this paper?

10.1007/s40258-023-00827-3, permanently at https://doi.org/10.1007/s40258-023-00827-3. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.